Your browser doesn't support javascript.
loading
Target Deconvolution Efforts on Wnt Pathway Screen Reveal Dual Modulation of Oxidative Phosphorylation and SERCA2.
Casás-Selves, Matias; Zhang, Andrew X; Dowling, James E; Hallén, Stefan; Kawatkar, Aarti; Pace, Nicholas J; Denz, Christopher R; Pontz, Timothy; Garahdaghi, Farzin; Cao, Qing; Sabirsh, Alan; Thakur, Kumar; O'Connell, Nichole; Hu, Jun; Cornella-Taracido, Iván; Weerapana, Eranthie; Zinda, Michael; Goodnow, Robert A; Castaldi, M Paola.
Afiliação
  • Casás-Selves M; Oncology, Innovative Medicines and Early Discovery Unit, AstraZeneca, 35 Gatehouse Drive, Waltham, MA, 02451, USA.
  • Zhang AX; Present address: Drug Discovery Program, Ontario Institute for Cancer Research, 661 University Avenue, Suite 510, Toronto, ON, M5G 0A3, Canada.
  • Dowling JE; Discovery Sciences-Chemical Biology, Innovative Medicines and Early Discovery Unit, AstraZeneca, 35 Gatehouse Drive, Waltham, MA, 02451, USA.
  • Hallén S; Oncology, Innovative Medicines and Early Discovery Unit, AstraZeneca, 35 Gatehouse Drive, Waltham, MA, 02451, USA.
  • Kawatkar A; Cardiovascular and Metabolic Diseases, Innovative Medicines and Early Discovery Unit, AstraZeneca, Pepparedsleden 1, Mölndal, 431 83, Sweden.
  • Pace NJ; Discovery Sciences-Chemical Biology, Innovative Medicines and Early Discovery Unit, AstraZeneca, 35 Gatehouse Drive, Waltham, MA, 02451, USA.
  • Denz CR; Department of Chemistry, Boston College, Chestnut Hill, MA, 02467, USA.
  • Pontz T; Oncology, Innovative Medicines and Early Discovery Unit, AstraZeneca, 35 Gatehouse Drive, Waltham, MA, 02451, USA.
  • Garahdaghi F; Oncology, Innovative Medicines and Early Discovery Unit, AstraZeneca, 35 Gatehouse Drive, Waltham, MA, 02451, USA.
  • Cao Q; Oncology, Innovative Medicines and Early Discovery Unit, AstraZeneca, 35 Gatehouse Drive, Waltham, MA, 02451, USA.
  • Sabirsh A; Present address: Synageva BioPharma Corp., 33 Hayden Avenue, Lexington, MA, 02421, USA.
  • Thakur K; Discovery Sciences-Computational Chemistry, Innovative Medicines and Early Discovery Unit, AstraZeneca, 35 Gatehouse Drive, Waltham, MA, 02451, USA.
  • O'Connell N; Present address: Ra Pharmaceuticals, Inc., 87 Cambridge Park Drive, Cambridge, MA, 02140, USA.
  • Hu J; Cardiovascular and Metabolic Diseases, Innovative Medicines and Early Discovery Unit, AstraZeneca, Pepparedsleden 1, Mölndal, 431 83, Sweden.
  • Cornella-Taracido I; Oncology, Innovative Medicines and Early Discovery Unit, AstraZeneca, 35 Gatehouse Drive, Waltham, MA, 02451, USA.
  • Weerapana E; Discovery Sciences-Structure and Biophysics, Innovative Medicines and Early Discovery Unit, AstraZeneca, 35 Gatehouse Drive, Waltham, MA, 02451, USA.
  • Zinda M; Present address: Nurix, Inc., 1700 Owens Street, Suite 290, San Francisco, CA, 94158, USA.
  • Goodnow RA; Discovery Sciences-Structure and Biophysics, Innovative Medicines and Early Discovery Unit, AstraZeneca, 35 Gatehouse Drive, Waltham, MA, 02451, USA.
  • Castaldi MP; Present address: Shire, 300 Shire Way, Lexington, MA, 02421, USA.
ChemMedChem ; 12(12): 917-924, 2017 06 21.
Article em En | MEDLINE | ID: mdl-28371485
ABSTRACT
Wnt signaling is critical for development, cell proliferation and differentiation, and mutations in this pathway resulting in constitutive signaling have been implicated in various cancers. A pathway screen using a Wnt-dependent reporter identified a chemical series based on a 1,2,3-thiadiazole-5-carboxamide (TDZ) core with sub-micromolar potency. Herein we report a comprehensive mechanism-of-action deconvolution study toward identifying the efficacy target(s) and biological implication of this chemical series involving bottom-up quantitative chemoproteomics, cell biology, and biochemical methods. Through observing the effects of our probes on metabolism and performing confirmatory cellular and biochemical assays, we found that this chemical series inhibits ATP synthesis by uncoupling the mitochondrial potential. Affinity chemoproteomics experiments identified sarco(endo)plasmic reticulum Ca2+ -dependent ATPase (SERCA2) as a binding partner of the TDZ series, and subsequent validation studies suggest that the TDZ series can act as ionophores through SERCA2 toward Wnt pathway inhibition.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Fosforilação Oxidativa / Tiadiazóis / ATPases Transportadoras de Cálcio do Retículo Sarcoplasmático / Via de Sinalização Wnt Limite: Humans Idioma: En Ano de publicação: 2017 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Fosforilação Oxidativa / Tiadiazóis / ATPases Transportadoras de Cálcio do Retículo Sarcoplasmático / Via de Sinalização Wnt Limite: Humans Idioma: En Ano de publicação: 2017 Tipo de documento: Article